COMBINATION OF AN HMG COA REDUCTASE INHIBITOR AND OTHER TYPE OF SERUM CHOLESTEROL REDUCING AGENT AND METHOD FOR LOWERING SERUM CHOLESTEROL USING SUCH COMBINATION

摘要

A pharmaceutical combination is provided which includes an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, such as lovastatin, pravastatin or velostatin, and a pharmaceutical which reduces serum cholesterol and/or inhibits cholesterol biosynthesis by a mechanism other than inhibiting production of the enzyme HMG CoA reductase, namely, probucol or niacin. A method for reducing serum cholesterol or inhibiting formation of or treating atherosclerosis using the above combination is also provided.